For the current week, the overall ratings of four Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Shire‘s (NASDAQ:SHPG) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. To get an in-depth look at SHPG, get Portfolio Grader’s complete analysis of SHPG stock.
The rating of Sagent Pharmaceuticals (NASDAQ:SGNT) slips from a C to a D. Sagent is an injectable pharmaceutical company that develops and sources products which they sell primarily in the United States. The stock gets F’s in Earnings Revisions and Equity. For a full analysis of SGNT stock, visit Portfolio Grader.
Pain Therapeutics (NASDAQ:PTIE) earns a D this week, falling from last week’s grade of C. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. The stock gets F’s in Equity and Sales Growth. The stock price has fallen 22.1% over the past month, worse than the 0.9% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PTIE stock.
Teva Pharmaceutical Industries‘s (NYSE:TEVA) rating weakens this week, dropping to a D versus last week’s C. Teva Pharmaceutical is a global company that develops, produces and markets generic drugs covering all major treatment categories. To get an in-depth look at TEVA, get Portfolio Grader’s complete analysis of TEVA stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.